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The herb Cannabis sativa has been traditional used in many cultures and all over the 12 
world for thousands of years as medicine and recreation. However, since it was brought 13 
to the Western world in the late 19th century, its use has been a source of controversy 14 
respect to its physiological effects as well as the generation of specific behaviors. In this 15 
regard, the CB1 receptor represents the most relevant target molecule of cannabinoid 16 
components on nervous system and whole-body energy homeostasis. Thus, the 17 
promotion of CB1 signaling can increase appetite and stimulate feeding, while blockade 18 
of CB1 suppresses hunger and induces hypophagia. Taste and flavor are sensory 19 
experiences involving the oral perception of food-derived chemicals and drive a primal 20 
sense of acceptable or unacceptable for what is sampled. Therefore, research within the 21 
last decades focused on deciphering the effect of cannabinoids on the chemical senses 22 
involved in food perception and consequently in the pattern of feeding. In this review, 23 
we summarize the data on the effect of cannabinoids on chemical senses and their 24 
influences on food intake control and feeding behavior. 25 
Keywords: endocannabinoids  , obesity  , sensory perception  , flavor  , synthetic 26 
cannabinoids   27 































































1. Introduction 28 
For more of 10,000 years, Cannabis sativa (C. sativa) has been used medically and 29 
recreationally for its diverse pharmacological actions and psychotropic properties in 30 
many cultures and all over the world. However, its use has been a source of controversy 31 
since it was brought to the Western world in the late 19th century due to its specific 32 
effects on physiology and behaviors. The study of C. sativa components has nonetheless 33 
contributed to discover various key elements of the endocannabinoid system (ECS). At 34 
the same time, the insight gathered about the ECS has helped to understand the 35 
mechanisms involved in the physiological/pharmacological effects of the bioactive 36 
components of C. sativa. 37 
Central regulation of feeding behavior is indispensable to energy homeostasis and to 38 
maintain essential daily functions (Gao and Horvath 2016) . The ECS is one of the ⁠39 
most prominent actors in the complex neural circuitry involved in this central regulation 40 
of energy homeostasis. Several studies revealed that endocannabinoids (eCBs), a highly 41 
conversed group of autacoids, play a role in central and peripheral regulation of energy 42 
balance (Nogueiras et al. 2010; O’Keefe et al. 2014) . Specifically, it has been shown ⁠43 
that stimulating CB1 signalling can induce adipogenesis (Vettor and Pagano 2009) and 44 
increase pancreatic insulin secretion (Juan-Pico et al. 2006), indicating that circulating 45 
eCBs may act as modulators of endocrine signals in peripheral organs (Hillard 2018). 46 
At the same time, energy status modulates eCB levels. For instance, it was shown that 47 
2-arachidonoylglycerol (2-AG), a representative eCB, increases specifically after acute 48 
food deprivation and decreases during feeding (Kirkham et al. 2002) . There is as well ⁠49 
a compelling amount of evidence suggesting that the dysregulation of the ECS 50 
contributes to obesity (Bluher et al. 2006) .⁠  51 
However, energy balance is not the only way through which the ECS influences 52 
feeding. An increasing number of studies in the last decade have shown that eCBs and 53 































































cannabinoid (CB) receptors participate in relevant processes of eating behavior, 54 
including reinforcement and reward processes (D’Addario et al. 2014; Gatta-Cherifi and 55 
Cota 2016), and food preference (Di Patrizio et al. 2013) . In a recent review, we ⁠56 
summarized much of the evidence on the role of the ECS on sweet taste perception, 57 
food preference and obesity (Tarragon and Moreno 2018) . In this review, we will try ⁠58 
to expand the coverage to how the ECS and especially exogenous cannabinoids (CBs) 59 
are involved in chemosensory perception (olfaction, gustation) and its influence on 60 
eating behavior and food intake control. 61 
 62 
2. The endocannabinoid system.  63 
The ECS comprises the eCBs, the enzymes/proteins that regulate their synthesis and 64 
degradation, and the receptors through which they signal. The identification of the 65 
tetrahydrol structure of cannabidiol (tetrahydrocannabinol, THC) was discovered in 66 
Cannabis sativa (C. sativa) in the 1940s (Adams et al. 1941). Years later, Gaoni and 67 
Mechoulam (1964) were able to identify the positioning of the ∆
9
, which confers THC 68 
(∆
9
-THC) its main  psychoactive properties . However, it was not until 1988 that the 69 
CB1 receptor was characterized (Devane et al. 1988; Gerard et al. 1991) . The ⁠70 
discovery of specific CB receptors implied the existence of endogenous ligands capable 71 
of activating these receptors, leading to propose the concept of an ECS (Howlett et al. 72 
1990) . This was rapidly confirmed by the isolation of the first endogenous CB ligand, ⁠73 
anandamide (AEA) (Devane et al. 1992) , the identification and characterization of the ⁠74 
CB2 receptor (Munro et al. 1993) , and the identification of a second endogenous ⁠75 
ligand, 2-arachidonoylglycerol (2-AG) a few years later (Mechoulam et al. 1995; Stella 76 
et al. 1997; Sugiura and Waku 2000). These and other lipid mediators capable of 77 
activating the CB receptors were named eCBs. Interestingly, these compounds were 78 
shown to activate several other receptors in addition to CB receptors, including the 79 































































transient receptor potential cation channel, subfamily V, member 1 (TPRV1) (Sartim et 80 
al. 2017)  and a novel orphan CB⁠  receptor GPR55 (Ryberg et al. 2007) . ⁠   81 
Today we know that eCBs serve as retrograde synaptic messengers within the central 82 
nervous system (CNS) (Pertwee and Ross 2002) . This suggests that eCBs act as both ⁠83 
neuromodulators and immunomodulators. The ECS functions have been characterized 84 
as “relax, eat, sleep, forget and protect” (Di Marzo 1998) , but the number of processes ⁠85 
in which the ECS participates increases each year with additional research discoveries. 86 
  87 
 88 
2.1. Cannabinoid receptors 89 
CB1 and CB2 receptors were first cloned by Matsuda et al. (1990)  and Munro et al. ⁠90 
(1993) , respectively. Both receptors are members of the G⁠ -protein-coupled receptors 91 
(GPCR) superfamily and are widely expressed in the brain (Moldrich and Wenger 2000; 92 
Gong et al. 2006). CB1 is one of the most abundant GPCR in the brain. 93 
Autoradiographic studies demonstrated that high levels of CB1 are expressed in the 94 
cortex, hippocampus, cerebellum,  basal ganglia, and the spinal cord (Herkenham et al. 95 
1990; Tsou et al. 1998; Freund et al. 2003), correlating with the well-known effects of 96 
CBs on cognition, memory,  motor control, and spinal signaling, respectively. The 97 
functional effects of the CB1 expression in the hypothalamus with respect feeding-98 
related patterns was described few years later (Breivogel et al. 1997; Elmquist et al. 99 
1999) .   This was further supported by ⁠ in situ hybridation studies that confirmed that 100 
CB receptors are found on axon terminals (Matsuda et al. 1993) , and by electron ⁠101 
microscope studies which also confirmed that cell-surface CB1 receptors are found 102 
almost exclusively on pre-synaptic terminals (Tsou et al. 1998; Katona et al. 2000) . ⁠103 
CB1 is also expressed in numerous peripheral tissues including heart, lung, prostate, 104 































































liver, ovaries and testis (Galiegue et al. 1995) , whereas CB⁠ 2 is abundantly expressed 105 
in peripheral organs with immune function (Galeigue et al. 1995) and up-regulated in 106 
response to immune cell activation and inflammation (Stella 2010) . Although it is ⁠107 
considered that the majority of the effects on the CNS are related with CB1 (Freund et 108 
al. 2003) , recent work has reported some functional expression of CB⁠ 2 receptor in the 109 
brain (Onaivi et al. 2006)  and that these may also be involved in eating behavior ⁠110 
(Onaivi et al. 2008)⁠ . 111 
Although CB1 and CB2 receptors are the most relevant CB receptors, it is likely that 112 
CBs can also act upon other GPCR, such as GPR18, GPR55 and GPR119. GPR55 was 113 
identified in the human brain by Sawzdargo et al. (1999)  and it can be considered  a ⁠114 
third CB receptor. ∆
9
-THC (Lauckner et al. 2005)  as well as synthetic CB⁠ 1 ligands 115 
such as AM251 or SR141716A (Kapur et al. 2009)  activate GPR⁠ 55, an “enigmatic” 116 
receptor that recent studies have linked to anorexia nervosa (Ishiguro et al. 2010) . In ⁠117 
addition, although GPR119 was not initially linked to ECS, Overton et al. (2006)  ⁠118 
showed that N-oleoylethanolamide (OEA), an analogue of AEA, also binds to this 119 
receptor. Interestingly, stimulating GPR119 with OEA suppresses feeding in rats 120 
(Rodríguez De Fonseca et al. 2001) ,.despi⁠ te this receptor not being directly involvedin 121 
central eCB-mediated feeding (Overton et al. 2006, 2008)  ⁠  122 
There is still much to clarify about how CBs produce their endogenous effects, and how 123 
these effects and other systems might interact with each other (Ben Amar 2006) . For ⁠124 
instance, the cross talk between the ECS and others such as the opioid system seems to 125 
modulate energy balance and food intake to a greater extent than either system alone 126 
(Morley and Levine 1982; Solinas and Goldberg 2005) . ⁠  127 
 128 
2.2. Endogenous cannabinoids 129 































































eCBs are derivatives of arachidonic acid (AA), resembling other lipid mediators such as 130 
eicosanoids. AA is conjugated with ethanolamine to form fatty acid amides such as 131 
AEA, or with glycerol to form monoacylglycerols, like 2-AG. AEA biosynthesis occurs 132 
in two steps. First, a calcium-dependent transacylase transfers an acyl group to 133 
membrane phospholipids in the N-position of phosphatidyletanolamine. This 134 
transference generates the N-acylphosphatidylethanolamines that selective 135 
phospholipases D hydrolyze to release AEA and phosphatidic acid (Okamoto et al. 136 
2004). 2-AG is mainly synthetized from AA-containing membrane phospholipids 137 
through the action of phospholipase C, leading to the formation of diacylglycerol 138 
hydrolyzed by diacylglycerol lipase (DAGL) (Bisogno et al. 2005) . Finally, AEA is ⁠139 
degraded by fatty acid amide hydrolase (FAAH), whereas 2-AG is degraded by 140 
monoacylglycerol lipase (MGL) or the α β serine hydrolase domain (ABHD) (Fig. 1). 141 
AEA resembles ∆
9
-THC in acting as a partial agonist at CB1 receptor. 2-AG is an 142 
agonist at both CB1 and CB2 receptors. However, other eCBs have been identified more 143 
recently, such as noladin (2-arachidonyl-glyceryl ether, 2-AGE) (Hanus et al. 2001) , ⁠144 
virhodamine (O-arachidonoyl-ethanolimine) (Porter 2002) , ⁠ N-arachidonyl-dopamine 145 
(Bisogno et al. 2000) , and oleamide (⁠ Cis-9,10-octadecanoamide) (Leggett et al. 146 
2004)  to name some.⁠  147 
 148 
2.3. Exogenous cannabinoids 149 
Exogenous CBs are natural molecules, mainly derived from plants (phytocannabinoids), 150 
and synthetic compounds that are able to bind to CB receptors and consequently 151 
interfere with the ECS functions, offering insights into the mechanisms of eCBs as well 152 
as bearing potential for future treatments. Depending on the source, they are defined as 153 
phytocannabinoids or synthetic CBs. 154 
































































2.3.1. Phytocannabinoids 156 
The cannabis plant contains more than 200 chemical compounds, including 120 157 
different phytocannabinoids, in addition to other constituents such as terpenoids and 158 
flavonoids (Radhakrishnan et al. 2014) . Together with cannabidiol (Russo ⁠ 2013) , 159 
∆
9
-THC is the best-studied CB, responsible for most of the pharmacological and 160 
psychoactive effects of C. sativa preparations. However, components of other plants 161 
besides cannabis have been reported to interact with CB receptors, binding to these and 162 
other CB-affine receptors, promoting diverse physiological effects as well. These 163 
components are named phytocannabinoids, a chemical class substance of C21 164 
terpenophenolic compounds (Mechoulam and Gaoni 1967)⁠  that were considered “a 165 
medicinal treasure trove which waits to be discovered” (Mechoulam 2007) . ⁠  166 
Examples of phytocannabinoids are also found in bark extract of Magnolia officinalis 167 
(Lee et al. 2011)  as well as in ⁠ Echinacea spp. (Gertsch et al. 2008)⁠ . On the other 168 
hand, sesquiterpene and caryophyllene, present in essential oils of Origarum vulgare, 169 
Cinnamomum spp., Piper nigrum, and C. sativa, are CB2 receptor agonists; some of 170 
them showing promising anti-inflammatory properties in recent, preliminary studies 171 
(Gertsch et al. 2008). Another phytocannbinoid newly discovered is cannabidivarin, 172 
which has shown effective anticonvulsant properties (Hill et al. 2012)  and efficacy as ⁠173 
an anti-epileptic agent through activation of CB receptors (Whalley et al. 2015) . Other ⁠174 
non-lipid derivatives, such as β-caryophyllene also present binding affinity for CB2 175 
(Gertsch et al. 2008).  176 
Nonetheless, binding to CB receptors is not the only characteristic to define a 177 
phytocannabinoid. For instance, N-acylethanolamines present no affinity for such 178 
receptors, although they are able to inhibit AEA degradation enzymes, thus promoting 179 































































eCB signaling (McPartland et al. 2014) . In addition, pristimerin and euphol, two ⁠180 
triterpenoids naturally occurring in several plants, have shown to inhibit MAGL and 181 
consequently the enzymatic degradation of 2-AG (Sawai and Saito 2011) . This ⁠182 
evidence indicates that exogenous CBs may not only act through direct binding to CB 183 
receptors, but also throughout different mechanisms that can modulate the ECS. 184 
 185 
2.3.2. Synthetic cannabinoids 186 
Synthetic CBs are a class of chemicals with the property of binding to CB receptors. 187 
Given the diverse actions and functions of the ECS within the organism, the 188 
development of synthetic CBs was an attempt to mimic the various physiological effects 189 
of eCBs avoiding their psychotropic consequences.  190 
Based in their chemical structures, CB agonists can be classified into at least four 191 
groups; classic CBs of C. sativa and its analogues, bicyclic and tricyclic analogues of 192 
∆
9
-THC, and non-classical CBs with structure of fatty amides or esters and 193 
aminoalkylindoles. Since the review of the hundreds of synthetic CBs is beyond the 194 
purpose of this work, we will name only a few of the most representative families (Fig. 195 
2).  196 
An example of synthetic ∆
9
-THC is 11-hydroxy- ∆
8
-THC dimethylheptyl (HU-210), a 197 
particularly potent CB that has efficacy at activating both CB1 and CB2 receptors 198 
(Mechoulam et al. 1988) . Specifically, HU⁠ -210 resembles the affinity for CB1 and 199 
CB2 receptors of other synthetic compounds like CP55,940 and WIN 55,212-2. The 200 
replacement of the pentyl side chain of ∆
8
-THC with a dimethylheptyl enhanced its 201 
affinity and efficacy at CB receptors (Pertwee 2006) . Non⁠ -classical CBs consisting of 202 
bicyclic and tricyclic analogues of ∆
9
-THC typically lack a pyran ring. The most 203 
commonly used ligand of this class is CP55,940, which has demonstrated relatively 204 































































high efficacy through both CB1 and CB2 receptors in the low nanomolar range (Pertwee, 205 
2005). The first cannabinergic indoles to be developed were amino-alkylindoles, among 206 
which WIN 55,212-2 showed a potent agonism to CB1 and CB2 receptors, binding 207 
differently to the CB1 receptor than classical and non-classical CBs (Compton et al. 208 
1992) .⁠  209 
  210 
3. Effect of cannabinoids on food intake control 211 
The mechanism behind the orexigenic effects of eCBs is still today a matter of active 212 
research. Although the observations that marijuana stimulates appetite and food 213 
consumption are known for many years (Abel 1971; Foltin et al. 1986) ,⁠  the 214 
experimental evidence for CB-induced hyperphagia has beenwas not demonstrated until 215 
more recently. In the late 1990s and early 2000s, Williams and co-workers 216 
demonstrated showed that ∆9-THC exerts hyperphagic action in pre-fed rats (Williams 217 
et al. 1998)  as well as free⁠ -feeding rats (Koch 2001) , a similar effect to that reported ⁠218 
using ∆8-THC (Avraham et al. 2004) . Additionally, numerous studies demonstrated ⁠219 
Kirkham et al (2002) reported that AEA and 2-AG levels are elevated by after food 220 
deprivation in the limbic forebrain, while 2-AG is reduced in the hypothalamus during 221 
the feeding state but increased during the deprived state, which suggests a role of eCBs 222 
in motivation towards food. Further, the reduction of 2-AG in the hypothalamus during 223 
feeding indicates that 2-AG can facilitate satiation (Kirkham et al. 2002) , suggesting a ⁠224 
role of eCBs in motivation towards food.  225 
Consistent with this idea, Di Patrizio and Simansky (2008) demonstrated that direct 226 
administration of 2-AG into the pontine parabrachial nucleus promoted high-fat, high-227 
sucrose, and high-fat and high-sucrose food intake while intake of standard pellets 228 
remained unaffected. Additionally, many studies show that acute infusion of CB1 229 































































agonists into distinct hypothalamic nuclei induce feeding, which provides evidence that 230 
the hypothalamic neurons are directly affected by CBs (Jamshidi and Taylor 2001; 231 
Koch et al. 2015). Concretely, it has been shown that CB1 agonism in the PVN 232 
increased hyperphagia in hungry mice and enhanced the hyperphagic effects of ghrelin 233 
in fed animals (Soria-Gómez et al. 2014a) . In the lateral hypothalamus, CB⁠ 1 is 234 
involved in physiological control of melanin-concentrating hormones and orexin-A 235 
neurons (Silvestri and Di Marzo 2013) . In the ARC, Agouti⁠ -related 236 
protein/neuropeptide Y (AgRP/NPY) neurons acutely promote food intake, and POMC 237 
neurons drive gradual onset of satiety (Varela and Horvath 2012) .  It was also ⁠238 
demonstrated that CB1 blockade in the hypothalamus reduced NPY levels, indicating 239 
local eCB control over AgRP/NPY neurons (Verty et al. 2009) . AgRP/NPY neurons ⁠240 
do not express CB1 (Cota et al. 2003) , but CB⁠ 1 is expressed at GABAergic terminals 241 
innervating AgRP/NPY neurons (Morozov et al. 2017) . This finding led to suggest ⁠242 
that eCBs might also promote feeding by retrograde inhibition of AgRP/NPY neurons. 243 
Coherent with the above mentioned, it has been shown that both AEA and 2-AG 244 
decrease the latency of feeding onset, increase the duration of intake and the number of 245 
meals, but only AEA increased total intake (Farrimond et al. 2011). These effects were 246 
reverted by SR 141716A, a CB1 inverse agonist (Landsman et al. 1997) , but not by ⁠247 
SR 144528, a CB2 antagonist (Williams and Kirkham 2002b) . Furthermore, WIN ⁠248 
55,212 similarly increased food intake, whereas SR 141716A reverted this effect 249 
(Gomez et al. 2002) . It was also demonstrated that daily administration of SR ⁠250 
141716A reduced food intake and body weight in Wistar rats (Colombo et al. 1998) . ⁠251 
More recently, Vickers et al. (2003)  demonstrated that oral, chr⁠ onic SR 141716A 252 
administration decreased food intake and body weight gain in both lean and obese 253 
Zucker rats and in diet-induced obese mice (Ravinet Trillou et al. 2003) . ⁠ Similarly, to 254 
SR 141716A, AM251 has shown to reduce food consumption in obese animals 255 































































(McLaughlin et al. 2003)  and in overnight⁠ -fasted animals (Shearman et al. 2003). 256 
Moreover, AM251 also produces dose-dependent reductions in reinforced response 257 
paradigms under fixed-ratio schedules (McLaughlin et al. 2003) . Taken together, ⁠258 
these data indicate that pharmacological manipulation of the CB receptors not only 259 
influences food consumption in total volume, but also appetitive response for food, and 260 
appears effective in controlling body weight and preventing weight-gain in experimental 261 
models of obesity. A series of relevant studies on this matter are gathered on Table 1. 262 
 263 
4. Cannabinoids and energy metabolism.  264 
It is well established that ECS is physiologically involved in the regulation of appetite, 265 
pain and inflammation, thermoregulation, intra-ocular pressure, sensation, muscle 266 
control, motivation and /reward, mood, memory, and appetite (Silvestri and Di Marzo 267 
2013). Furthermore, it has been suggested a link between eCBs and high prevalence 268 
pathophysiological states, including obesity, metabolic syndrome, diabetes (Perkins and 269 
Davis 2008; Pacher and Kunos 2013)  and cardiovascular disease (Chanda et al. ⁠270 
2017) .⁠  Indeed, upon stimulation, the ECS through eCBs increases food intake and 271 
weight gain, promotes lipogenesis and impairs glucose tolerance (Cota et al. 2003) , ⁠272 
and modulates growth (Li et al. 2013) . ⁠  273 
Recently, Simon and Cota (2017)  reviewed the effect of ⁠ CBs on metabolism. They 274 
reported that CB1 receptor activation increases lipogenesis and adipogenesis, impairs 275 
mitochondrial biogenesis, favors the white adipocyte phenotype, and that, in the liver, 276 
CB1 receptor exerts a critical role in the regulation of lipid metabolism and insulin 277 
sensitivity. In this way, Miederer et al. (2017)  reported that THC was able to affect ⁠278 
the glucose uptake in the rat brain, which may be of relevance in behavioral studies. 279 
Interestingly, CB1 is involved in the regulation of food intake by digestive system and 280 































































insulin release by pancreatic islets. Furthermore, we must consider that some of these 281 
metabolic effects of CB ligands could be related, at least in part, with alternative 282 
receptors such as GPR55 (Tudurí et al. 2017) .⁠  283 
Hypothalamic CB1 signaling also interfaces with signal transmission of metabolic 284 
hormones. For instance, while leptin-suppressed feeding correlates with decreased 285 
hypothalamic eCBs levels (Di Marzo et al. 2001) , ghrelin⁠ -triggered feeding depends 286 
on paraventricular nucleus (PVN) CB1 signaling and accompanies increased 287 
hypothalamic eCB levels (Kola et al. 2008) . ⁠ The activation of AMP-activated protein 288 
kinase (AMPK) has been proposed as a molecular mechanism by which the CBs might 289 
exert its effects on eating behavior (Kola et al. 2005) . AMPK plays a central role in ⁠290 
the control of energy homeostasis at both individual cellular level and globally in the 291 
organism (Hardie 2008) . Furthermore, various studies demonstrate that eCBs activate ⁠292 
AMPK in the hypothalamus, enhancing orexigenic signals, while decreasing fat 293 
oxidation in fat tissue and liver (Tedesco et al. 2010) . Interestingly, several feeding⁠ -294 
related hormones such as leptin, ghrelin and adiponectin can also influence AMPK 295 
activity (Kola et al. 2008) . The hi⁠ ghly active interaction between ECS and many of 296 
such endocrine and paracrine elements suggests a mediating role of eCBs on hormone 297 
functioning. This idea is supported by various studies showing data for 298 
heterodimerisation of CB receptors with the orexin (Ellis et al. 2006) , opioid (Hojo et ⁠299 
al. 2008) , type ⁠ )  and ghrelin (Edwards and Abizaid ⁠ )  ⁠2 dopamine (Kearn 2005 2016300 
receptors. 301 
Additionally, we must consider that, although to a lesser extent, the CB2 in the CNS has 302 
also shown to be involved in glucose homeostasis and led to a lean phenotype (Romero-303 
Zerbo et al. 2012) . Recent localization of CB⁠ 2 receptors in metabolically active tissues 304 
suggests that this receptor might also have a significant role in energy homeostasis and 305 
body weight regulation. Accordingly, Verty et al. (2015)  observed that JWH⁠ -015, a 306 































































CB2 agonist, reduced food intake, fat mass and adipocyte cell size in lean and obese 307 
mice without any adverse impact on mood. Thus, in the interest of pursuing improved 308 
pharmacotherapy treatment involving the eCB, it would be negligent to exclude a role 309 
of CB2 agonist/antagonists as putative target in the future of obesity-related treatments. 310 
Surprisingly, it was recently described that CB1 receptor activation in the POMC 311 
neurons is also relevant for the hyperphagic properties of CBs, acting at pre- and post-312 
synaptic levels (Koch et al. 2015) . The stimulation of CB⁠ 1 receptors in these POMC 313 
neurons inhibits the synthesis of the α–melanocyte-stimulating hormone (α-MSH) but 314 
not β-endorphin peptides, a process mediated via mitochondrial activation (Koch et al. 315 
2015) . Further, CB⁠ 1 receptors co-exist in POMC neurons with orexin-A receptors, 316 
whose stimulation initiate the synthesis of 2-AG thus promoting hyperphagia even in 317 
sated rats (Morello et al. 2016) . Finally⁠ , it was also reported that CB1 signaling 318 
modulates dopaminergic signaling in the nucleus accumbens and ventral tegmental area 319 
(Di Marzo et al. 2009a) , a phenomenon that has been direct⁠ ly related to the attribution 320 
of salience to stimuli in general and food in particular (Salamone and Correa 2012, 321 
2013) .⁠  322 
Importantly, hypothalamic AgRP/NPY and POMC neurons are not only directly 323 
affected by food intake itself, but also rapidly respond to sensory detection of available 324 
food (Chen et al. 2015) . Thus, hypothalamus not only regulates hunger and satiety in ⁠325 
response to eating and internal signals of energy resources, but also receives external 326 
information on the incentive value of food, such as sight, smell, and taste (Seeley and 327 
Berridge 2015) . ⁠  328 
 329 
5. Cannabinoid-based pharmacotherapy in obesity 330 































































Interestingly, in addition to its orexigenic effects, THC has been reported to be 331 
anorexigenic as well. While low, oral doses of THC increase acute food intake, higher 332 
doses decrease feeding when administered systemically (Sofia and Knobloch 1976) . ⁠333 
Other studies also indicate that the hyperphagic effect produced by is not long-lasting 334 
(Järbe and Di Patrizio, 2005). Hence, CBs and eCBs seem to have a biphasic effect on 335 
feeding, which is to say that different levels of stimulation lead to opposite outcome. 336 
Further, many studies report elevated levels of circulating eCB in obese individuals 337 
(Engeli et al. 2005;⁠  Di Marzo et al. 2009b; Matias et al. 2012. Little et al. 2018). Since 338 
eCBs levels are increased in both the food deprived and in obesity, the theory that eCB 339 
dysfunction plays an important role in this condition seems especially relevant.  340 
A recent examination of two US national surveys identified a lower prevalence of 341 
obesity in cannabis users (Le Foll et al. 2013) . These observations are paradoxical ⁠342 
considering previous reports of acute cannabis stimulating appetite and food intake. 343 
However, preclinical studies also support this observation, showing that both lean and 344 
obese animals decreased body weight after chronic combined administration of CBD 345 
and THC (Klein et al. 2011) . Interestingly, this reduction in energy intake was also ⁠346 
observed after the chronic administration of THC alone, an effect which has been 347 
attributed to interactions with the gut microbiota (Cluny et al. 2015) . Thus, chronic ⁠348 
agonism of the ECS may be an under-explored therapeutic strategy in treating obesity. 349 
The mechanism underlying the relationship between chronic cannabis use and absence 350 
of obesity is unclear. However, provided that THC is a partial agonist and may 351 
functionally act as an antagonist under conditions of high eCB tone such as in obesity 352 
(Le Foll et al. 2013), chronic cannabis use may share a similar mechanism of action to 353 
Rimonabant (Acomplia®) and other CB1 antagonist in preventing weight gain.  In this 354 
regard, Rimonabant was approved as an anti-obesity drug by European Union, UK and 355 
USA after clinical trials conducted by Sanofi-Aventis successfully showed weight loss, 356 































































a decrease in plasma triglycerides, a reduction of waist circumference, and an increase 357 
in high density lipoprotein cholesterol (HDL) (Van Gaal et al. 2005; Despreś et al. 358 
2006; Pi-Sunyer et al. 2006).  359 
Unfortunately, Rimonobant was discontinued due to an increased risk of depression and 360 
suicide after continuous use. Since this withdrawal, other CB1 antagonist drugs have 361 
been halted in the process of development. Taranabant (Merch & Co.) also induced 362 
weight loss (Addy et al. 2008) , although phase III trials were stopped in October ⁠ 2008 363 
due to a high level of central side effects, including anxiety and depression. 364 
Interestingly, Willimas and Kirkham (2002a) observed that ∆
9
-THC-induced 365 
hyperphagia could be attenuated by the opioid antagonist naloxone, which provides 366 
further evidence of the aforementioned link between opioid food reward processing and 367 
the ECS (Koch et al. 2015). Promisingly, Dronabinol (Marinol®), an oral preparation of 368 
∆
9
-THC, and nabilone (Cesamet®), a synthetic analogue of ∆
9
-THC are already 369 
licensed for clinical use in some countries as appetite stimulants and attenuating weight 370 
loss associated to anorexia (Verty et al. 2011)  or AIDS (Badowski and Perez ⁠ 2016) . 371 
A key aspect of the history of pharmacological strategies targeting the ECS in managing 372 
obesity and metabolic disorders is the severe affective symptomatology and/or the focus 373 
on neurobiological systems involved in the affective response. This is interesting in the 374 
context of this review, since depression and anxiety disorders often co-exist with 375 
alterations in chemosensory perception (Parker et al. 2014; Takahashi et al. 2015; 376 
Taalman et al. 2017; Hur et al. 2018) . Traditionally, it is assumed that the alte⁠ rations 377 
in chemosensory response are consequence of the neurobiochemical changes induced by 378 
depression-like states. However, the opposite direction of this relationship has never 379 
been tested. How is it to know that disturbances in perception do not act as a trigger for 380 
altered, negative mood? Indeed, there is evidence showing that changes in taste can 381 
affect mood (Karita et al. 2012; Platte et al. 2013; Sugawara et al. 2013)⁠  382 
































































6. Effect of cannabinoid on chemo perception 384 
Taste and flavor are sensory experiences involving the oral perception of food-derived 385 
chemicals and drive a primal sense of acceptable or unacceptable for what is sampled. 386 
Therefore, deciphering the effect of CB on the perception of chemical senses and 387 
consequently in the pattern of feeding has been a focus of interest within the CB 388 
research in the last decades. There is considerable amount of evidence describing the 389 
participation of the ECS on the chemosensory response to food (Ward and Dykstra 390 
2005; Yoshida et al. 2010). Specifically, circulating eCBs influence olfactory 391 
perception, with differences between lean and obese individuals (Pastor et al. 2016). 392 
Additionally, the activation of CB1 has been shown to enhance gustatory properties of 393 
food in both animals and humans (Limebeer et al. 2012; Niki et al. 2015) . Other ⁠394 
studies show that the processing of olfactory or gustatory sensations involves CB1 395 
signaling (Table 2). For instance, fasted mice displayed CB1 dependent increased odor 396 
detection in the olfactory bulb (Soria-Gómez et al. 2014b) . As described above, CB ⁠397 
receptors and other CB-binding receptors (i.e. TPRV1) are not only modulated by eCBs 398 
and ∆
9
-THC, but also by other phytocannabinoids like cannabidiol (Campos et al. 399 
2013)  and other synthetic CBs (Castaneto et al. ⁠ 2014)⁠ . In this section, we 400 
summarize relevant research covering the effect of the ECS and CBs on smell and taste, 401 
as primary chemosensory processes relevant to food choice and food intake. 402 
 403 
6.1. Cannabinoids and smell 404 
Smell is one of the primary senses among mammals. In humans, contributes drastically 405 
to experience flavor not only as a chemosensory response, but also as an important 406 
component of the affective response to food (Stevenson 2009) . The olfactory ⁠407 































































information is processed within brain regions also associated with the processing of 408 
cognitive and affective information (i.e. amygdala, hippocampus, PFC). Many studies 409 
show that olfactory perception is affected in metabolic disturbed states, including 410 
obesity but also anorexia and bulimia nervosa (Richardson et al. 2004; Palouzier-411 
Paulignan et al. 2012; Karine et al. 2014; Soria-Gómez et al. 2014c). Furthermore, it 412 
was recently demonstrated that smell is associated with central and peripheral systems 413 
that regulate food intake. Interestingly, people with obesity show significant differences 414 
regarding olfactory capacity in comparison with healthy subjects (Richardson et al. 415 
2004; Pastor et al. 2016) . And this has been shown even in children (Jansen et al. ⁠416 
2003) . Thus, the olfactory system can influence eating⁠  behavior by acting on hunger 417 
and satiety signals as a sort of metabolic regulator, hence affecting energy homeostasis 418 
(Yeomans 2006; Palouzier-Paulignan et al. 2012) . ⁠  419 
One of the systems with which olfaction interacts closely is the ECS (Palouzier-420 
Paulignan et al. 2012). From basic organisms to humans, experimental evidence 421 
demonstrates the close participation of the ECS on olfactory function. For instance, 422 
Breuning and colleagues showed that hunger-induced 2-AG synthesis in the olfactory 423 
epithelium increases neuron activity and controls odor sensory threshold via CB1 424 
activity in larvae X. laevis (Breunig et al. 2010) . Interestingly, despite these ⁠425 
properties, it seems that eCBs do not modulate olfaction per se (Hutch et al. 2015).  426 
Further evidence shows that one of the mechanisms through which the ECS stimulates 427 
eating behavior is smell. This is coherent with findings of numerous CB1 receptors in 428 
terminal axons project towards the olfactory bulb (Busquets-Garcia et al. 2015) . In a ⁠429 
series of experiments, Soria-Gomez and colleagues demonstrated that AEA, 2-AG and 430 
THC increased odor detection and food intake in fasted mice by decreasing signal input 431 
from the olfactory cortex to the olfactory bulb (Soria-Gómez et al. 2014b) . Also, it is ⁠432 
known that ECS-interacting endocrine and paracrine hormones involved in the hunger-433 































































satiety processes can influence smell thresholds (Ketterer et al. 2011; Thanos et al. 434 
2013) . And evidence from clinical studies indicates that the activation of the CB ⁠435 
receptors enhances smell, taste, and has an orexigenic effect (Støving et al. 2009; 436 
Brisbois et al. 2011). 437 
Recently, some research investigated the participation of phytocannabinoids and 438 
synthetic CBs on smell. It was recently demonstrated that WIN-55212-2 and WIN-439 
55212-3, are capable of binding to CB1 and CB2 receptors in neurons of the olfactory 440 
bulb, not affecting olfactory function (Hutch et al. 2015). Considering the resurgence of 441 
THC in medical use, including neuropathic pain or analgesia treatment in cancer, it is 442 
important to assess the olfactory effects of phytocannabinoids and synthetic CBs. 443 
Walter et al. (2014)  reported that ⁠ ∆9-THC impaired the performance of healthy 444 
volunteers in olfactory tests. Furthermore, these authors demonstrated that THC-445 
induced reduction in the pleasantness of a pleasurable odor was accompanied by 446 
reduced activation in the limbic system. These findings suggest that THC-based 447 
medications will be among the drugs displaying side effects on chemoperception. 448 
Interestingly, when THC was administered to cancer patients with chemosensory 449 
alterations, THC was effective in palliating chemosensory alterations and improving 450 
food enjoyment (Brisbois et al. 2011). 451 
 452 
6.2. Cannabinoids and taste 453 
Smell is not the only chemosensory system interacting with the ECS to modulate 454 
feeding. Gustatory perception is also closely related to the ECS, and genetic variations 455 
of various elements within the ECS has shown to also influence taste and food 456 
preference (De Luis et al. 2010, 2013b, 2013a, 2016a, 2016b), together with other 457 
processes related to eating behavior, such as reward sensitivity (Hariri et al. 2009), 458 































































binging (Monteleone et al. 2009)  and cravings (Haughey et al. ⁠ 2008).  Thus, the 459 
perception of taste is also essential for the assessment of edibility of food and for the 460 
evaluation of its nutritional values. For instance, a polymorphism in the CB1 receptor 461 
gene (CNR1), the (AAT)n, is associated with changes in the sensitivity to sweetness. 462 
Concretely, the sweetness threshold in women with obesity that carried was 463 
significantly lower compared to those without the (AAT)n repeat (Umabiki et al. 464 
2011) . ⁠  465 
Yoshida and colleagues (2010) observed that the administration of AEA and 2-AG 466 
increased taste responses to sweet rather than salty, sour, bitter or umami flavors in 467 
wild-type but not in CB1 knock-out animals. This effect has been further explored as an 468 
opposite action of the anorexigenic hormone leptin (Yoshida et al. 2010; Niki et al. 469 
2015). These opposite effects of eCBs and leptin on sweet taste were also confirmed by 470 
Jyotaki et al. (2010) . However, Wierucka et al. (⁠ )  reported that CB⁠2014 1 antagonist, 471 
AM251, attenuated body weight gain in rats maintained on high-calorie rich in fat and 472 
carbohydrates but did not affect preferences for sweet food. Thus, the effects of ECS 473 
and CBs on sweet taste seem to be still controversial. 474 
Interestingly, some evidence indicates that circulating levels of eCB can also modulate 475 
bitterness sensitivity in non-overweight individuals (Tomassini Barbarossa et al. 2013; 476 
Tepper et al. 2014) . Furthermore, the ECS seems to participate in the gustatory ⁠477 
perception of fats (Di Patrizio 2014) . According to various studies, the ECS is ⁠478 
specifically related to the perception of one kind of unsaturated fatty acids (FA), as the 479 
presence of saturated FA failed to stimulate the synthesis of eCB in the small intestine 480 
(Mindell et al. 1990; Di Patrizio et al. 2011, 2013) . However, these findings should be ⁠481 
considered carefully, since physiological differences between humans and rodents may 482 
affect FA taste sensitivity thresholds (Kawai and Fushiki 2003; Stewart et al. 2010). All 483 































































together suggest that eCBs and CBs seem to constitute a selective reinforcement signal 484 
for palatable food. 485 
Finally, given the relevance on taste in regards hedonic salience to food, there is an 486 
increasing interest in elucidating the mechanisms behind the affective response to 487 
different foods. It seems clear that the ECS plays an important part on this process. 488 
Pharmacological studies provide strong evidence to support this. For instance, 489 
CP55,940 increases beer and sucrose consumption whereas both SR 141716A, a CB1 490 
antagonist, and naloxone block these effects on spontaneous sucrose drinking (Higgs et 491 
al. 2003)  and operant responding for sucrose (McLaughlin et al. ⁠ 2003), suggesting a 492 
role of CB1 and opioid receptors (Gallate et al. 1999)  in these behaviors. In this way, ⁠493 
Simiand et al. (1998)  reported that SR ⁠ 141716A reduced consumption of a highly 494 
palatable sweetened food and suggested that eCBs may modulate “the appetitive value 495 
of food”. However, other authors have challenged this idea. Particularly, the results 496 
obtained by Freedland et al. (2000)  suggested that appetitive value or enhanced ⁠497 
palatability was not necessary to the anorectic effects of this CB1 antagonist. Recently, 498 
Wakeford et al. (2016)  observed that THC exposure had no effect on taste ⁠499 
conditioning in adolescent animals. However, de Brujin and colleagues investigated 500 
whether low doses of inhaled ∆
9
-THC and cannabidiol affected sweet taste sensitivity, 501 
reported no change in sweet sensitivity either perception or subjective response (i.e. 502 
liking) after inhalation of the various cannabis preparations (de Bruijn et al. 2017) . It ⁠503 
is also worth mentioning that Jarret et al. (2005)  observed that THC increases intake ⁠504 
of palatable (sweet) food 2 hours, but not earlier, following a low dose of THC, an 505 
effect that involved CB1 receptor and can partially explain the above apparent 506 
incongruities. On the other hand, SR 141716A is sufficient to attenuate the reinforcing 507 
effect of fat, while activation of the central CB1 system is enough to enhance its 508 
reinforcement properties (Ward and Dykstra 2005) .⁠  509 































































Apparently, the debate on the role of the ECS and CBs on food-related affective 510 
response is not over, and it will be necessary more studies on this topic. Unfortunately, 511 
the research on the role of the ECS and CBs on chemosensory response is not as 512 
abundant as in other fields. With the increasing rate of dysfunctional dietary habits, we 513 
believe this should be neglected no longer. 514 
CB2 is a recent guest to this history. β-caryophyllene, a CB2 agonist, was used to 515 
investigate the role of this receptor in mediating alcohol intake and ethanol-induced 516 
conditioned place preference and sensitivity in rodents. Specifically, β-caryophyllene 517 
decreased alcohol consumption and ethanol-induced place preference in a dose-518 
dependent manner but did not alter taste function. Interestingly, this effect was 519 
abrogated by a selective CB2 receptor antagonist (AM630) (Al Mansouri et al. 2014) , ⁠520 
thus suggesting a connection between the CB2 receptor and ethanol consumption and 521 
representing a potential novel pharmacological target for the treatment of alcoholism. In 522 
this way, Marcus et al. (2017)  reported that mutant mice expressing a “hyper⁠ -523 
sensitive” form of CB1 show similar taste preference for sucrose, quinine and alcohol 524 
and did not change ethanol consumption. 525 
 526 
7. Effects of cannabinoids on food flavor and on peripheral mechanisms to the control 527 
of feeding pattern 528 
Flavor corresponds to the combination of sensations that includes taste, odor and 529 
trigeminal inputs. Innate and learned flavor preferences influence food and drink 530 
choices (see Tarragon and Moreno 2017 for a more in-depth description of the role of 531 
the ECS on food preference). It has a major role in the final (gestalt) perception and 532 
enjoyment of food, thus being considered the main endogenous factor for food 533 
preferences and intake (Bodnar 2016) . ⁠  534 































































The two primary forms of learned preferences involve flavor-flavor and flavor-nutrient 535 
associations. In these, a specific flavor element (e.g., odor) is paired with an innately 536 
preferred flavor element (e.g., sweet taste) and/or with a positive post-oral nutrient 537 
consequence (i.e. higher energy available) (Touzani et al. 2010) . It has been proposed ⁠538 
that these two dimensions of learned preferences are driven by related albeit different 539 
neural mechanisms, among which the dopaminergic, the opioid and the eCBs are of 540 
remarked relevance. Given the scope of this review, we will focus primarily on the 541 
latter.  542 
Pharmacological manipulations of CB1 receptors with eCBs, synthetic CBs,  ∆
9
-THC 543 
and other phytocannabinoids are widely reported among the literature on eating 544 
behavior (Gamage and Lichtman 2012) . For instance, the exogenous administration of ⁠545 
AEA has proved to affect eating pattern by reducing the latency to food consumption, 546 
and by increasing the size of the meal and consumption duration (Hao et al. 2000; 547 
Jamshidi and Taylor 2001; Williams and Kirkham 2002a). Also, the administration of 548 
dronabiol (a synthetic CB), ∆
9
-THC, THC-derived phytocanabinnoids, and non-THC-549 
derived phytocannabinoids are capable of stimulating feeding behavior in rats (Williams 550 
and Kirkham 2002b; Farrimond et al. 2010, 2012a, 2012b) . According to these ⁠551 
studies, the enhanced feeding response is mediated by the activation of the CB1 552 
receptor. Further, CB1 agonist did not only increased total volume of food, but also 553 
affected other parameters of feeding pattern including the aforementioned delay to food 554 
and meal size, two features that mostly fall within the flavor-flavor category mentioned 555 
above.  556 
In the 1970s some of the first experimental studies investigating the effects of THC on 557 
food intake in humans reported significant increases in consumption of chocolate milk 558 
shakes and marshmallows (Abel 1971) , a finding which now underlines the two main ⁠559 
aspects of the ECS in modulating both appetite and the hedonic of highly palatable 560 































































foods such as sweets and fats (Harrold and Williams 2003) . The implication of CB⁠ 1 561 
receptor in human weight homeostasis has also been confirmed measuring CB1 562 
availability by positron emission tomography in volunteers and patients with food 563 
eating disorders (FED) such as anorexia nervosa, bulimia nervosa, and also in obesity 564 
(Ceccarini et al. 2016) . More specifically, data shows an inverse association between ⁠565 
CB1 receptor availability and body mass index (BMI) in the hypothalamus and the 566 
brainsteam in healthy subjects and patients with food eating disorders both. However, 567 
other brain regions involved in the processing of reward and hedonic value of food (i.e. 568 
striatum, insula, amygdala, and OFC) only correlated with BMI in FED patients. 569 
Coherent with this, a recent study showed that cannabivarin, a CB1 antagonist, increased 570 
responses to chocolate stimuli and to aversive stimuli in the amygdala, the insula and 571 
the OFC (Tudge et al. 2015) . ⁠  572 
A recent study shows that the hyperphagia observed in obese mice that followed a 573 
typical western style diet for 60 days is dependent on CB1 receptors. Specifically, the 574 
inhibition of peripheral CB1 receptors reduced food consumption in the western diet but 575 
not in the standard diet group (Argueta and Di Patrizio 2017) . This information is ⁠576 
coherent with other studies showing that smell can enhance response to food via CB1 577 
receptors in terminal axons project towards the olfactory bulb (Soria-Gómez et al. 578 
2014b; Busquets-Garcia et al. 2015) . In addition, Mathes and colleagues demonstrated ⁠579 
that the blockade of CB1 receptors is able to prevent body weight by selectively 580 
decreasing the selection of fattening foods in an obesity-induced protocol in rats 581 
(Mathes et al. 2008) .⁠  582 
Interestingly, another recent study showed that there is no difference when comparing 583 
the administration of phytocannabinoids, synthetic CBs, and eCBs with respect body 584 
weight regulation, food intake, and glucose homeostasis (Marcus et al. 2016) . Also, it ⁠585 
has been shown that cannabidiol does not affect negatively the affective response to 586 































































emotional stimuli in humans (Arndt and de Wit 2017) . Despite that this study was ⁠587 
carried out with facial stimuli, the results from Arndt and de Wit could provide a 588 
starting point to explore the effect of phytocannabinoids and synthetic CBs on other 589 
levels of the emotional continuum, like the affective response to food.  590 
It has also been observed that the presence of fat in the oral cavity induces a cephalic-591 
phase response resulting in jejunal production of eCBs, further linked with increased fat 592 
intake (Di Patrizio et al. 2011) . It was hypothesized that this effect might be triggered ⁠593 
by ghrelin, since gastric CB1 activation leads to ghrelin secretion, which increases fat-594 
taste perception and promotes fat intake (Perello et al. 2010). Interestingly, salivary 595 
eCBs are found in higher concentration in obese patients in comparison with healthy 596 
subjects (Matias et al. 2012)⁠  and might be associated with ω-6/ω-3 ratio intake 597 
(Zimmer et al. 2018, unpublished data). Further, eCBs can increase neural response 598 
specifically to sweet taste through a CB1-dependent mechanism (Yoshida et al. 2010).  599 
Considering that ECS can also modulate olfactory responses, it is worth noting the role 600 
of this system in the regulation of sensory information (flavor) associated with food 601 
intake and feeding pattern. Both exogenous and endogenous CBs strongly stimulate 602 
intake of sugars and fats in particular (Koch 2001; Kirkham 2005) . Moreover, it has ⁠603 
been observed that CB1 antagonism reduced the expression of fructose-conditioned 604 
flavor preference while failing to affect the acquisition of such preference (Miner et al. 605 
2008) . ⁠  606 
The evidence presented indicates that modifications in the strength of learned flavor 607 
associations could influence behavior towards food. Moreover, given the motivational 608 
properties of palatability, manipulating these flavor-flavor and flavor-nutrient 609 
associations could serve as a therapeutic tool in illnesses where taste perception is 610 
altered, thus potentiating adherence to the treatment. Unfortunately, despite all the 611 































































information collected around the CB system and the flavor-flavor dimension, the role of 612 
CB1 in flavor-nutrient learning has yet to be investigated. 613 
There is no literature, to the best of our knowledge, covering the affective response to 614 
food after the administration of CB derivatives nor synthetic CBs. It is reasonable to 615 
hypothesize that the same operating mechanisms for eCBs and ∆
9
-THC are operating in 616 
the brain, thus exerting similar effects regarding energy homeostasis and the regulation 617 
of eating behavior (Fig. 3). However, as mentioned, the experimental evidence to claim 618 
this is circumstantial. 619 
The evidence on human subjects with respect the effect of ECS on feeding pattern is not 620 
as numerous as in rodent models. Ethical concerns with respect the use of THC-621 
derivatives with potential psychotropic effects on the volunteers maybe a reason for the 622 
limited number of studies. Hence, synthetic and non-psychotropic THC derivatives may 623 
represent a promising alternative to study how the ECS participates in eating behavior 624 
in general, and in chemosensory response to food, particularly. Thus, THC and ghrelin 625 
have been proposed in the palliation of chemosensory alterations (dysgeusia) to improve 626 
food enjoyment (Vancleef et al. 2015; Sun et al. 2016) . A growing number of studies ⁠627 
currently focus on this promising area, although more research is needed to fully grasp 628 
the potential implication of these CB-related compounds on smell, taste, and other 629 
properties of the eating experience.  630 
 631 
8. Conclusion 632 
Since the isolation of the psychoactive component of the C. sativa in the early 1960s, 633 
hundreds of CB derivatives have been discovered in plants and developed in 634 
laboratories. All these compounds bind to a certain degree to specific CB receptors 635 
located both in the brain and peripherally, from where regulate and modulate a great 636 































































deal of physiological and psychological processes. Some of these compounds present 637 
promising properties as therapeutic drugs for several conditions, particularly in those 638 
related to obesity. Unfortunately, the amount of research covering the putative effects of 639 
phytocannabinoids and synthetic CBs on metabolic-related disorders is remarkably 640 
scarce, particularly in regard to relevant aspects of eating behavior, such as smell, and 641 
sweet and fat taste sensitivity. In this review, we summarized the role of the ECS in 642 
chemosensory perception, given it is pivotal function in eating behavior. Understanding 643 
that the ECS also affects energy homeostasis through its influence on how taste and 644 
smell are perceived is relevant for developing better strategies targeting body weight 645 
homeostasis disruption-related conditions. Further, we believe that both 646 
phytocannabinoids and synthetic CB compounds would be promising pharmacological 647 
alternatives in the treatment of high prevalence diseases such as obesity, type 2 diabetes 648 
and metabolic syndrome.  649 
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Table 1. Brief overview of the main CB receptor ligands, giving basic information and effects on food intake and body weight 1263 
Ligand Original report Company 
Commercial 
name 
CB1 CB2 Similar molecules Effect on food intake Effect on body weight 
2-AG  Mechoulam et al., 1995   Ag Ag  ↑(Lambert & Muccioli 2007) ↑(Kirkham 2005) 
AEA Devane et al., 1992   Ag Ag oleoylethanolamide ↑(Lambert & Muccioli 2007) ↑(Kirkham 2005)                                                                                                              




Ag Ag   
↑(Jarbe and Di Patrizio, 
2005) 
∆9THCV Gill et al., 1970   Ag Ag  ↓(Riedel et al. 2009) ↓(Riedel et al. 2009) 
CBD 
Adams and Baker, 
1940 
  Ag Ag   ↓(Ignatowska et al. 2011) 
HU-210 Mechoulam, 1988  Hebrew Univ. Dexanabinol Ag Ag 
HU211, HU239, HU243, 
HU308, HU320, HU345 
 ↓(Giuliani et al. 2000) 
CP 55,940 Little et al., 1988 Pfizer  Ag Ag CP 47,497   
CP945,598 Kim et al., 2008  Pzifer Otenabant Antag   ↓(Hadcock et al. 2010) ↓(Hadcock et al. 2010) 
































































AM251 Gatley et al., 1996 Sanofi Aventis  Antag   ↓(Riedel et al. 2009) ↓(Riedel et al. 2009) 
AM630 Pertween et al., 1995 Sanofi Aventis  Drinabant Antag Antag    
AM4113 Sink et al., 2007 Sanofi Aventis  Antag Antag  ↓(Cluny et al. 2011) ↓(Cluny et al. 2011) 
AM6545 




 Antag Antag  ↓(Cluny et al. 2011) ↓(Tam et al., 2010) 
JWH015  Huffman et al., 1994 John W Huffman  Ag Ag JWH018, JWH133   
MK0364 Arstrong et al., 2007 Merck  Taranabant Antag   ↓(Fong et al. 2007) ↓(Fong et al. 2007) 






↓ (Horswill et al. 2007) ↓(Horswill et al. 2007) 
O-2050 Martin et al., 2002 
Virginia Commm 
Univ. 
 Antag  O2113, O2372, O2545 ↓(Gardner and Mallet 2006)  




Antag  SR147778 (Surinabant) ↓(Jarbe and Di Patrizio, 2005)  
SR144528 Rinaldi et al., 1998 Sanofi Aventis  Antag  
UR12, UR144, JWH203, 
MDA19, WIN55,225, 
  

































































SM-11 Fois et al., 2016 University of Sassari   Antag  NESS06SM  ↓(Fous et al., 2016) ↓(Fous et al., 2016) 
WIN55212-2 Pacheco et al., 1991   Ag  CP55,940 ↑(Merroun et al., 2009)  
 LY320135 Felder et al., 1998 Elli Lilly   Antag     
  1264 
































































Table 2. Summary of studies exploring the influence of the ECS on chemosensory perception 1265 
Reference Ligand Effect on ECS Effect on chemosensory perception 
Simiand et al., 1998 SR141716A CB1 antag Selectively reduced sweet food intake compared to standard food pellets. 








Facilitates response acquisition for sweetened and fatty solutions following a progressive ratio learning protocol. 
Impairs enhanced response for sweetened and fatty solutions following a progressive ratio learning protocol. 
Czesnik et al., 2007 
AM281, AM251, and 
LY320135 
CB1 antag Diminish and delay food odor responses. 





CB1 and CB2 ag 
Impaired pontine parabrachial nucleus response, associated with the gustatory properties of food. 
Strong increase of fat and sucrose, sucrose, and fat intake. 
Breuning et al., 2010 
RHC80267, OMDM-
187, and OMDM-188 
HU210 
DAG lipase blockers 
 
CB1 ag 
The delay and amplitude of individual olfactory response neurons were prolonged in the presence of odorants. 
 
Restored olfactory sensitivity and lowered the olfactory sensitivity threshold. 




CB1 and CB2 ag 
CB1 antag 
CB2 antag 
Increases gustatory response to sweeteners but not to salty, sour, bitter, and umami compounds. 
Diminishes gustatory response to sweeteners. 
Does not affect gustatory response to sweeteners. 
Brisbois et al., 2011 THC CB1 ag 
Improved improved and enhanced chemosensory perception and gustatory response in chemotherapy patients. 
































































Umabiki et al., 2011 (AAT)12 repeat CB1 receptor gene Higher sweet sensitivity threshold in non carriers of the (AAT)12 repeat gene, coding for the CB1 receptor.  




CB1 antag  
Cannabinoid agonism/antagonism regulates neuron firing patterns in the glomeruli of the main olfactory bulb. 
DiPatrizio et al., 2013 AM6546, URB447 CB1 antag Diminishes preference for solutions rich in monoenoic and dienoic fatty acids, observed in non-treated rats. 
Barbarossa et al., 2013 AEA, 2-AG CB1 and CB2 ag 
Highly sensitive individuals to 6-n-propylthiouracil showed greater levels of plasmatic AEA and 2-AG compared to individuals with 
lower sensitivity. 









CB1 and CB2 ag 
Administration into the granular layer of the main olfactory bulb reduced intake in fasted mice with elevated levels of AEA. 
 
Administration into the granular layer of the main olfactory bulb enhanced fasting-induced food intake. 
Niki et al., 2015 AM251 CB1 antag 
Enhanced response for sweetened solution impaired in lean mice, but not genetically obese or diet-induce obese mice. Genetically 
obese mice showed increased levels of 2-AG and DAGL in taste cells after the administration of AM251. 
Pastor et al., 2016 AEA, 2-AG CB1 and CB2 ag 
Threshold-discrimination-identification capacity was associated with lower 2-AG and higher body fat percentage in obese women 
compared to non-obese women.  
de Brujin et al., 2017 THC, CBD CB1 and CB2 ag 
When inhaled, neither THC nor CBD affected sweetness sensitivity threshold, liking, or ad libitum consumption of the preferred drink. 
Food preference was not affected neither.  
































































Figure 1. Synthesis of synthetic, phyto-, and endocannabinoids. Schematic 1266 
representation of the synthesis process from which synthetic cannabinoids, 1267 
phytocannabinoids and endocannabinoids are obtained.  1268 
































































Figure 2. Synthetic, phyto-, and endocannabinoids. Here there are some of the most 1269 
popular among the hundreds of cannabinoid molecules discovered since the 1970s.  1270 
































































Figure 3. Chemosensory response and the ECS. The molecular reaction initiated by the 1271 
perception of aromas is entangled with the ECS functioning. As well as by endogenous 1272 
and exogenous cannabinoids, CB receptors are activated by the chemosensory response 1273 
in the olfactory bulb and along the brain circuitry involved in the emotional and 1274 
cognitive effect triggered by taste and smell. This activity is afterwards involved in 1275 
several physiological and psychological aspects of eating behavior, such as developing 1276 
preferences for certain tastes and foods, and even modulating food intake.  1277 

































































Synthesis of synthetic, phyto-, and endocannabinoids. Schematic representation of the synthesis process 
from which synthetic cannabinoids, phytocannabinoids and endocannabinoids are obtained.  
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Synthetic, phyto-, and endocannabinoids. Here there are some of the most popular among the hundreds of 
cannabinoid molecules discovered since the 1970s.  
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Chemosensory response and the ECS. The molecular reaction initiated by the perception of aromas is 
entangled with the ECS functioning. As well as by endogenous and exogenous cannabinoids, CB receptors 
are activated by the chemosensory response in the olfactory bulb and along the brain circuitry involved in 
the emotional and cognitive effect triggered by taste and smell. This activity is afterwards involved in 
several physiological and psychological aspects of eating behavior, such as developing preferences for 
certain tastes and foods, and even modulating food intake.  
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